Table 2 Univariate analysis of prognostic factors
LRC | DC | FFTF | OS | |||||
|---|---|---|---|---|---|---|---|---|
1-yr rate | p value | 1-yr rate | p value | 1-yr rate | p value | 1-yr rate | p value | |
Gender | ||||||||
Male | 63% | 0.192 | 81% | 0.464 | 57% | 0.33 | 43% | 0.443 |
Female | 44% | 78% | 44% | 60% | ||||
Age | ||||||||
< 75 yrs | 54% | 0.523 | 78% | 0.572 | 50% | 0.652 | 30% | 0.236 |
≥ 75 yrs | 63% | 80% | 57% | 58% | ||||
Charlson score | ||||||||
≤ 1 | 61% | 0.901 | 83 | 0.493 | 58% | 0.991 | 51% | 0.041 |
> 1 | 56% | 74 | 55% | 33% | ||||
Histology | ||||||||
SCC | 62% | 0.484 | 86% | 0.121 | 57% | 0.456 | 50% | 0.107 |
Adenocarcinoma | 55% | 63% | 47% | 36% | ||||
Localization | ||||||||
Cervical | 80% | 0.335 | 80% | 0.427 | 60% | 0.267 | 60% | 0.249 |
Upper thoracic | 71% | 100% | 71% | 33% | ||||
Middle thoracic | 51% | 76% | 47% | 47% | ||||
Lower thoracic | 59% | 77% | 53% | 61% | ||||
Grading | ||||||||
G2 | 63% | 0.853 | 80% | 0.811 | 57% | 0.818 | 53% | 0.238 |
G3 | 53% | 79% | 48% | 39% | ||||
T stage | ||||||||
T1–3 | 59% | 0.911 | 83% | 0.374 | 55% | 0.559 | 56% | 0.002 |
T4 | 78% | 78% | 67% | 9% | ||||
N stage | ||||||||
N0 | 70% | 0.201 | 93% | 0.035 | 64% | 0.161 | 44% | 0.921 |
N+ | 54% | 72% | 49% | 48% | ||||
time period | ||||||||
before 2008 | 42% | 0.061 | 84% | 0.366 | 35% | 0.048 | 24% | < 0.001 |
after 2008 | 67% | 80% | 64% | 66% | ||||
PET-CT Staging | ||||||||
yes | 66% | 0.085 | 80% | 0.866 | 61% | 0.101 | 63% | < 0.001 |
no | 27% | 86% | 25% | 17% | ||||
RT sequence | ||||||||
neoadj | 100% | 0.022 | 100% | 0.146 | 100% | 0.014 | 71% | 0.055 |
definitive | 53% | 77% | 47% | 43% | ||||
RT technique | ||||||||
3D-CRT | 59% | 0.638 | 83% | 0.918 | 53% | 0.508 | 43% | 0.076 |
IMRT | 75% | 75% | 75% | 80% | ||||
Chemotherapy | ||||||||
no | 30% | 0.351 | 86% | 0.481 | 28% | 0.24 | 50% | 0.317 |
yes | 64% | 80% | 61% | 46% | ||||
LRC | ||||||||
no | 87% | 0.054 | 37% | 0.605 | ||||
yes | 72% | 63% | ||||||